Piper Sandler raised the firm’s price target on Merit Medical (MMSI) to $109 from $105 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 results that once again beat at both the top and bottom lines with 8% organic revenue growth and 9c EPS beat, but it may have been the gross margin upside in Q3 that was most impressive in the period. Full year guidance was raised as well, but in typical Merit Medical fashion Piper sees the implied guide for Q4 as being set in a prudent/responsible way.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Cautious Hold Rating for Merit Medical Systems Amid Strong Q3 and Transitional Challenges
- Merit Medical Systems: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Merit Medical Reports Strong Q3 2025 Growth
- Merit Medical Systems Reports Strong Q3 2025 Results
- Merit Medical raises FY25 EPS view $3.66-$3.79 from $3.52-$3.72